Stockscreener 앱 받기
5.50
0.00%
0.00
시간 외 거래:
5.40
-0.10
-1.82%
전일 마감가:
$5.50
열려 있는:
$5.665
하루 거래량:
55,513
Relative Volume:
0.74
시가총액:
$17.64M
수익:
-
순이익/손실:
$-37.68M
주가수익비율:
-0.4647
EPS:
-11.8364
순현금흐름:
$-30.65M
1주 성능:
-1.26%
1개월 성능:
+5.36%
6개월 성능:
-41.80%
1년 성능:
+1,265%
1일 변동 폭
$5.30
$5.83
1주일 범위
$4.92
$5.9387
52주 변동 폭
$0.3195
$20.00
Passage Bio Inc Stock (PASG) Company Profile
명칭
Passage Bio Inc
전화
(267) 866-0312
주소
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
5.50 | 17.64M | 0 | -37.68M | -30.65M | -11.84 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2026-04-21 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2026-04-21 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2026-03-31 | 개시 | Oppenheimer | Outperform |
| 2026-02-10 | 재개 | Chardan Capital Markets | Buy |
| 2024-11-29 | 재개 | Wedbush | Outperform |
| 2024-09-03 | 개시 | Rodman & Renshaw | Buy |
| 2022-03-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-01-19 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-07-01 | 개시 | Raymond James | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-03-04 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-02-04 | 개시 | Guggenheim | Buy |
| 2021-01-25 | 개시 | Wedbush | Outperform |
| 2021-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-11 | 개시 | Citigroup | Neutral |
| 2020-08-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2020-03-24 | 개시 | Cowen | Outperform |
| 2020-03-24 | 개시 | Goldman | Buy |
| 2020-03-24 | 개시 | JP Morgan | Overweight |
모두보기
Passage Bio Inc 주식(PASG)의 최신 뉴스
Layoff Tracker: Genentech R&D cuts include longtime top exec - BioSpace
Passage Bio Inc. (PASG) Surges Over 9% as Biotech Stock Tests Key ResistanceEarnings Quality Factor - newsline.com
Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Neumora cuts 35% - Fierce Biotech
Guggenheim Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo
Passage Bio (PASG) Downgraded to Neutral as Strategic Review Ini - GuruFocus
Passage Bio (PASG) Slides 6.33% as Stock Approaches Key Support at $5.34SuperTrend - newsline.com
Thryv Holdings Faces Continued Pressure as Shares Slide to $3.72Dollar Neutral Pair - newsline.com
Passage Bio Inc. (PASG) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentGAAP Earnings Report - newsline.com
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SentimentAnalyst Consensus Shift - newsline.com
Passage Bio Inc. (PASG) Edges Higher as Buyers Defend Key Support LevelCumulative Volume - The Legal Advocate
Delhi Airport Becomes First Indian Infrastructure Facility to Deploy 'Skycast' Aviation Weather Intelligence SystemGAAP Earnings Report - newsline.com
Unusual Machines (UMAC) Surges 57% as Momentum Builds Above Key SupportInstitutional Sentiment - The Legal Advocate
Passage Bio Ends Gemma Collaboration, Philadelphia Office Lease - Moomoo
Passage Bio Ends Key Collaborations and Office Lease - TipRanks
Passage Bioterminates research, collaboration and license agreement with Gemma Bio Therapeutics - marketscreener.com
Passage BIOTerminates Research, Collaboration And License Agreement With Gemma BIO Therapeutics - TradingView
Passage Bio (NASDAQ: PASG) ends Gemma deal, pays $2.3M to exit lease - Stock Titan
Passage Bio Inc. (PASG) Q1 2026 Earnings: Narrower-Than-Expected Loss Fuels Share GainsOne-Time Gain Impact - newsline.com
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionUpward Estimate Revision - The Legal Advocate
PASG Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Market ResponseEarnings Volatility Report - The Legal Advocate
Passage Bio, Inc. 2026 Annual Meeting Results: Stockholder Votes and Key Corporate Information (Form 8-K) - Minichart
Passage Bio Shareholders Approve Directors and Executive Pay - TipRanks
Passage Bio (NASDAQ: PASG) holders choose annual say-on-pay at 2026 meeting - Stock Titan
PASG Technical Analysis & Stock Price Forecast - Intellectia AI
Barnes & Noble Education Inc (BNED) Surges 6.36%: Key Levels to WatchWMA Signal - newsline.com
PASG Q1 2026 Earnings: Narrower-than-expected loss lifts sharesAnalyst Consensus Shift - thelegaladvocate.com
Passage Bio Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentCEO Earnings Statement - The Legal Advocate
PASG Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Operational ProgressCrowd Sentiment Entry - Newser
Passage Bio Inc. (PASG) Holds Steady Near Support as Biotechnology Sector Faces HeadwindsBeta Neutral Pair - Newser
Director Sondhi Dolan receives 10,539 Passage BIO (PASG) stock options - Stock Titan
Passage BIO (NASDAQ: PASG) director Derrell Porter receives grant of 10,539 stock options - Stock Titan
Passage BIO, Inc. (PASG) director gets 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) director Sandip Kapadia awarded 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) director receives 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) awards 10,539 options to director at $5.08 - Stock Titan
Passage Bio Inc stock (US70267E1055): gene therapy developer back in focus after recent moves - AD HOC NEWS
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside? - Insider Monkey
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Passage Bio Inc stock (US70267E1055): gene therapy hopes meet analyst caution - AD HOC NEWS
Gene Therapy In CNS Disorder Therapeutics Market Size in the 7MM - openPR.com
Passage Bio stock (US70267E1055): Cuts 75% of workforce after FDA feedback - AD HOC NEWS
Passage Bio, Inc.Common Stock (NQ: PASG - FinancialContent
TradingKey - TradingKey
Indian Stock Market Rises: Sensex Gains 50 Points, Nifty 50 Holds Above 23,400Slow Growth Warning - newsline.com
Krabbe Disease Treatment Market to Reach USD 786.45 Million - openPR.com
TD Cowen Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo
MSN Money - MSN
GM1 Gangliosidosis Treatment Market to Reach USD 626.86 Million - openPR.com
Passage BIO, Inc. 1Q 2026: Net loss $(7.6)M, EPS $(2.36) — 10-Q Summary - TradingView
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Passage Bio (NASDAQ: PASG) faces cash shortfall, cuts workforce 75% - Stock Titan
Passage Bio Inc (PASG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Passage Bio Inc 주식 (PASG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Borthwick Kathleen | CFO |
Jan 08 '26 |
Sale |
18.44 |
2,062 |
38,022 |
5,402 |
1.27%
1.43%
자본화:
|
볼륨(24시간):